Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Caution evidenceCoverage 1/5 core metricsFlagged areas: Dilution.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- 1 filing risk check flagged
Flagged areas: Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-10-21
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Clinical Stage Bio Technology-$17.3M86.2%+39.5% yoy
- Digital Asset Treasury-$2.77M13.8%no prior
Members sum to the consolidated -$20.1M for this period.
- Other Revenue$1.3M87.2%no prior
- Network Validation Revenue$191K12.8%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 4,060 US-listed filers · 883 in Financials| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Return on equity net income ÷ stockholders' equity (positive equity only) | -9.0% | 34thof 3,520 middle third | 14thof 752 bottom third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -7.6% | 64thof 3,845 middle third | 87thof 837 top third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 14 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | quarter 2023-09-30 | 17,294,113 shares 10-Q 2023-11-07 | 46,169 shares 10-Q 2024-11-07 | -99.7% | first · latest |
| Basic shares WeightedAverageNumberOfSharesOutstandingBasic | quarter 2023-09-30 | 17,294,113 shares 10-Q 2023-11-07 | 46,169 shares 10-Q 2024-11-07 | -99.7% | first · latest |
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | quarter 2023-06-30 | 14,950,408 shares 10-Q 2023-08-11 | 44,889 shares 10-Q 2024-08-09 | -99.7% | first · latest |
| Basic shares WeightedAverageNumberOfSharesOutstandingBasic | quarter 2023-06-30 | 14,950,408 shares 10-Q 2023-08-11 | 44,889 shares 10-Q 2024-08-09 | -99.7% | first · latest |
| Diluted shares WeightedAverageNumberOfDilutedSharesOutstanding | quarter 2024-03-31 | 11,757,808 shares 10-Q 2024-05-09 | 885,683 shares 10-Q 2025-05-12 | -92.5% | first · latest |
| Basic shares WeightedAverageNumberOfSharesOutstandingBasic | quarter 2024-03-31 | 11,757,808 shares 10-Q 2024-05-09 | 885,683 shares 10-Q 2025-05-12 | -92.5% | first · latest |
| Total liabilities Liabilities | balance at 2022-03-31 | $1.02M 10-Q 2022-05-16 | $1.75M 10-K/A 2023-05-22 | +72.4% | first · latest |
| Total liabilities Liabilities | balance at 2022-06-30 | $745K 10-Q 2022-08-11 | $1.21M 10-K/A 2023-05-22 | +62.0% | first · latest |
| Operating cash flow NetCashProvidedByUsedInOperatingActivities | quarter 2022-03-31 | -$2.01M 10-Q 2022-05-16 | -$2.73M 10-Q 2023-05-22 | -36.0% | first · latest · 3 filings carry it |
| Total liabilities Liabilities | balance at 2022-09-30 | $717K 10-Q 2022-11-14 | $902K 10-K/A 2023-05-22 | +25.9% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2025-06-30 | -$1.85M 10-Q 2025-08-14 | -$1.43M 10-Q 2026-08-14 | +22.8% | first · latest |
| Total assets Assets | balance at 2022-03-31 | $11.4M 10-Q 2022-05-16 | $12.1M 10-K/A 2023-05-22 | +6.5% | first · latest |
| Total assets Assets | balance at 2022-06-30 | $9.79M 10-Q 2022-08-11 | $10.2M 10-K/A 2023-05-22 | +4.7% | first · latest |
| Total assets Assets | balance at 2022-09-30 | $7.83M 10-Q 2022-11-14 | $8.02M 10-K/A 2023-05-22 | +2.4% | first · latest |
4 share-count periods re-presented for a stock split (1-for-25, 1-for-15) are listed apart from restatements and not counted above.
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
Not available for CNTN yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.